Axon Enterprise, Inc (NASDAQ:AXON) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lowered its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 39.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,088 shares of the biotechnology company’s stock after selling 1,333 shares during the period. Atria Wealth Solutions Inc.’s holdings in Axon Enterprise were worth $1,098,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Capital World Investors grew its holdings in shares of Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock valued at $1,079,145,000 after purchasing an additional 841,772 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after purchasing an additional 212,931 shares in the last quarter. GAMMA Investing LLC raised its holdings in Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company’s stock valued at $402,210,000 after acquiring an additional 763,431 shares in the last quarter. Northern Trust Corp raised its holdings in Axon Enterprise by 19.8% in the fourth quarter. Northern Trust Corp now owns 716,926 shares of the biotechnology company’s stock valued at $426,083,000 after acquiring an additional 118,469 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after acquiring an additional 611,418 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $818.69 on Tuesday. The firm’s fifty day moving average price is $775.48 and its 200 day moving average price is $666.90. Axon Enterprise, Inc has a 1-year low of $346.71 and a 1-year high of $885.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The firm has a market cap of $64.27 billion, a price-to-earnings ratio of 202.15, a price-to-earnings-growth ratio of 30.92 and a beta of 1.36.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%. The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same quarter last year, the company earned $1.20 earnings per share. Axon Enterprise’s quarterly revenue was up 32.6% compared to the same quarter last year. On average, sell-side analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a report on Thursday, July 17th. The Goldman Sachs Group raised their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a report on Wednesday, May 14th. UBS Group reaffirmed a “neutral” rating and issued a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Bank of America raised their target price on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Finally, Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price on the stock in a report on Tuesday, August 5th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and an average target price of $837.69.

Insider Buying and Selling

In other news, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of Axon Enterprise stock in a transaction on Monday, May 19th. The stock was sold at an average price of $738.84, for a total transaction of $960,492.00. Following the completion of the transaction, the director owned 4,829 shares of the company’s stock, valued at $3,567,858.36. The trade was a 21.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Joshua Isner sold 905 shares of Axon Enterprise stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total value of $702,632.95. Following the transaction, the president directly owned 268,735 shares of the company’s stock, valued at $208,643,166.65. This trade represents a 0.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,585 shares of company stock valued at $16,100,838 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.